Prevalence of Hepatitis C Virus Infection, Genotypes and Subtypes in Migrants from Pakistan in Barcelona, Spain

Background Hepatitis C virus (HCV) is a major cause of chronic liver infection with 71 million people infected worldwide. Pakistan has the second highest prevalence of HCV infection and more than half (52%) of Pakistani living in Spain reside in Barcelona. The aim of this study was to analyse the seroprevalence and viraemic rate and determine the genotypes and subtypes of HCV among Pakistanis living in the southern metropolitan area of Barcelona. Methods We included all Pakistani patients seeking primary healthcare in the southern metropolitan area of Barcelona from August 2011 to July 2014. Serum samples were screened for HCV antibodies. HCV viral load was determined by reverse transcription polymerase chain reaction and genotypes and subtypes were performed using Versant HCV Genotype and/or deep-sequencing. Screening for hepatitis B virus (HBV) was also carried out. Results Among 5877 Pakistani patients, 565 (9.61%) were screened for anti-HCV antibodies, with 68 (12.04%) being positive. The viral load was determined in 65, with 31 presenting active infection and the viraemic rate was 47.69% (95% confidence interval 36.02–59.62). HCV genotyping and subtyping were performed in 24 individuals. Most infections corresponded to HCV genotype 3 (91.67%), and high resolution HCV subtyping was performed in 18 samples, 16 of which presented subtype 3a. One subject presented HBV coinfection with undetectable HBV DNA. During the study period, we identified a possible case of HCV vertical transmission followed by spontaneous viraemia clearance in a chronically infected mother with a C/T IL28B genetic polymorphism. Conclusion These results suggest that general HCV screening protocols in patients from high prevalence countries, such as Pakistan, would be helpful to identify and treat active HCV infections. This could avoid further transmission and contribute to building targeted health policies for micro-elimination of HCV infection in specific communities.

[1]  D. Benjamin,et al.  Infection and Drug Resistance , 2022 .

[2]  R. Taherkhani,et al.  Prevalence and Predominant Genotype of Hepatitis C Virus Infection and Associated Risk Factors among Pregnant Women in Iran , 2021, BioMed research international.

[3]  J. Quer,et al.  Significant Improvement in Diagnosis of Hepatitis C Virus Infection by a One-Step Strategy in a Central Laboratory: an Optimal Tool for Hepatitis C Elimination? , 2019, Journal of Clinical Microbiology.

[4]  M. Maciá,et al.  Whole-genome characterization and resistance-associated substitutions in a new HCV genotype 1 subtype , 2019, Infection and drug resistance.

[5]  J. Pineda,et al.  Hepatitis C virus infection in Spain: Challenges in the track to elimination. , 2019, Enfermedades infecciosas y microbiologia clinica.

[6]  J. Lazarus,et al.  Hepatitis C prevalence among the migrant population in Spain: A systematic review and meta-analysis. , 2019, Enfermedades infecciosas y microbiologia clinica.

[7]  Manfred Seiler Register , 2019, Pflege und Strafrecht.

[8]  A. Jamal,et al.  Correlation of IL28B rs12979860 genotype and gender with spontaneous clearance of HCV infection: a Pakistani cross-section study. , 2018, Personalized medicine.

[9]  Y. Yazdanpanah,et al.  Assessing the cost-effectiveness of hepatitis C screening strategies in France. , 2018, Journal of hepatology.

[10]  Jean-Michel Pawlotsky,et al.  EASL Recommendations on Treatment of Hepatitis C 2018. , 2018, Journal of hepatology.

[11]  H. Mo,et al.  Identification of a Novel Hepatitis C Virus Genotype From Punjab, India: Expanding Classification of Hepatitis C Virus Into 8 Genotypes , 2018, The Journal of infectious diseases.

[12]  B. Crespo-Facorro,et al.  Microenvironment Eradication of Hepatitis C: A Novel Treatment Paradigm , 2018, The American Journal of Gastroenterology.

[13]  B. Berkhout,et al.  High Treatment Uptake in Human Immunodeficiency Virus/Hepatitis C Virus–Coinfected Patients After Unrestricted Access to Direct-Acting Antivirals in the Netherlands , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  L. Abu-Raddad,et al.  The epidemiology of hepatitis C virus in Pakistan: systematic review and meta-analyses , 2018, Royal Society Open Science.

[15]  J. Pawlotsky,et al.  A novel standardized deep sequencing-based assay for hepatitis C virus genotype determination , 2018, Scientific Reports.

[16]  S. Olafsson,et al.  Treatment as Prevention for Hepatitis C (TraP Hep C) – a nationwide elimination programme in Iceland using direct‐acting antiviral agents , 2018, Journal of internal medicine.

[17]  T. Qadir,et al.  Tackling hepatitis C—Pakistan's road to success , 2018, The Lancet.

[18]  I. Veldhuijzen,et al.  Estimating the scale of chronic hepatitis C virus infection in the EU/EEA: a focus on migrants from anti-HCV endemic countries , 2018, BMC Infectious Diseases.

[19]  Josephine G. Walker,et al.  Curbing the hepatitis C virus epidemic in Pakistan: the impact of scaling up treatment and prevention for achieving elimination , 2018, International journal of epidemiology.

[20]  Pei-Jer Chen,et al.  Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV. , 2017, Gastroenterology.

[21]  G. Indolfi Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection , 2018 .

[22]  J. Lazarus,et al.  Micro-elimination - A path to global elimination of hepatitis C. , 2017, Journal of hepatology.

[23]  S. El-Kamary,et al.  Spontaneous Viral Load Decline and Subsequent Clearance of Chronic Hepatitis C Virus in Postpartum Women Correlates With Favorable Interleukin-28B Gene Allele , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  Reza Taherkhani,et al.  Lurking epidemic of hepatitis C virus infection in Iran: A call to action , 2017, World journal of hepatology.

[25]  Ofer Peleg,et al.  HCV Genotype-1 Subtypes and Resistance-Associated Substitutions in Drug-Naive and in Direct-Acting Antiviral Treatment Failure Patients , 2017, Antiviral therapy.

[26]  M. Manns,et al.  Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. , 2017, The lancet. Gastroenterology & hepatology.

[27]  Gamal Esmat,et al.  Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. , 2017, The lancet. Gastroenterology & hepatology.

[28]  U. Ashfaq,et al.  Epidemiology of Hepatitis C Infection in Pakistan: Current Estimate and Major Risk Factors. , 2017, Critical reviews in eukaryotic gene expression.

[29]  Un Desa Transforming our world : The 2030 Agenda for Sustainable Development , 2016 .

[30]  H. Wickham Simple, Consistent Wrappers for Common String Operations , 2015 .

[31]  A. Flaxman,et al.  Global Distribution and Prevalence of Hepatitis C Virus Genotypes , 2014, Hepatology.

[32]  C. Tremblay,et al.  Hepatitis C Virus Genotype 7, a New Genotype Originating from Central Africa , 2014, Journal of Clinical Microbiology.

[33]  E. Domingo,et al.  High-Resolution Hepatitis C Virus Subtyping Using NS5B Deep Sequencing and Phylogeny, an Alternative to Current Methods , 2014, Journal of Clinical Microbiology.

[34]  H. Razavi,et al.  Global epidemiology and genotype distribution of the hepatitis C virus infection. , 2014, Journal of hepatology.

[35]  F. Ullah,et al.  Prevalence of Hepatitis C Virus Genotypes in District Bannu, Khyber Pakhtunkhwa, Pakistan , 2014, Hepatitis research and treatment.

[36]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[37]  Steven Salzberg,et al.  BIOINFORMATICS ORIGINAL PAPER , 2004 .

[38]  Sanaullah Khan,et al.  Hepatitis C virus genotypes in Pakistan: a systemic review , 2011, Virology Journal.

[39]  M. Idrees,et al.  Hepatitis C virus genotype 3a with phylogenetically distinct origin is circulating in Pakistan , 2011, Genetic vaccines and therapy.

[40]  R. Jooma,et al.  Prevalence of hepatitis B and C viral infections in Pakistan: findings of a national survey appealing for effective prevention and control measures. , 2010, Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit.

[41]  Robert Gentleman,et al.  ShortRead: a bioconductor package for input, quality assessment and exploration of high-throughput sequence data , 2009, Bioinform..

[42]  S. Vermund,et al.  Hepatitis B and hepatitis C in Pakistan: prevalence and risk factors. , 2009, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[43]  M. Khalid,et al.  High prevalence of hepatitis C virus infection in the largest province of Pakistan , 2008, Journal of digestive diseases.

[44]  S. Sarin,et al.  Distribution of hepatitis C virus genotypes in patients with chronic hepatitis C infection in India. , 2004, The Indian journal of medical research.

[45]  Korbinian Strimmer,et al.  APE: Analyses of Phylogenetics and Evolution in R language , 2004, Bioinform..